[A19-71] Ivacaftor (combination with ivacaftor/tezacaftor, cystic fibrosis, 12 years and older, with F508del mutation, heterozygous) - Benefit assessment according to §35a Social Code Book V
|2019-12-02||Extract of dossier assessment||481 kB|
|2019-12-02||Dossier assessment (German version)||798 kB|
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Extract of dossier assessment
Federal Joint Committee (G-BA)
2020-02-20 A G-BA decision was published.